LncRNA MEG3 acts a biomarker and regulates cell functions by targeting ADAR1 in colorectal cancer

Table 2 Clinicopathological characteristics in our study

	Tissue samples, n = 42	Serum samples
		Colorectal cancer, n = 126	Healthy controls, n = 48
Age
mean ± SD	56.8 ± 6.5	56.9 ± 5.9	56.3 ± 6.4
Median (range)	57 (44-73)	58 (38-74)	58 (38-73)
Gender
Male	27	85	33
Female	15	41	15
Tumor site
Colon	17	58
Rectum	25	68
Tumor size in cm
≥ 5	12	43
< 5	30	83
pT, TNM
T1+T2	33	93
T3+T4	9	33
Lymph node metastasis
Positive	18	71
Negative	22	55
Clinical stage, TNM
III	13	72
I+II	29	54
Pathological differentiation	26	59
Well/moderate Poor	16	67
high vs low
Lymph node metastasis, positive vs negative	0.988
	0.225
Clinical stage of	0.440
TNM, III vs I + II	2.789
Pathological differentiation, well/moderate vs poor
Serum lncRNA
MEG3 expression,

TNM: Tumor node metastasis.